Glofitamab,Obinutuzumab,Tocilizumab
roche
['glofitamab', 'lymsm', 'obinu', 'lymphoma', 'dlbcl']
good news if you are in the 39.4% of patients w dlbcl achieving cr following 12 cycles of glofitamab - responses are promisingly durable so far, with the significant benefit of fixed duration treatment #ash22 #lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer